ASCO 2024: Latest in mRCC treatment

Share :
Published: 3 Jun 2024
Views: 1098
Rating:
Save
Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas Powles

Dr Sumanta Kumar Pal (City of Hope, California, USA), Prof Thomas Powles (Barts Cancer Centre, London, UK), Prof Viktor Grünwald (University Hospital Essen, Essen, Germany) and Dr Stephanie Berg (Dana-Farber Cancer Institute, Boston, USA) discuss the latest updates in mRCC.

The panel talks about the multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.

They also discuss the phase 3 CLEAR, KEYNOTE-426 and CheckMate 67T trials.

Belzutifan in patients with advanced clear cell renal cell carcinoma was also discussed.

This programme has been supported by an unrestricted educational grant from Eisai.